ATP2C1

Across TCGA pan-cancer cohorts, ATP2C1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ATP2C1 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ATP2C1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP2C1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

SCLC, LIHC, and UCEC are the cancer types where ATP2C1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	III,IV	0.082	0.548	.003	24	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.874	0.305	.030	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
COAD	DFS	Median	All	0.148	0.564	.023	3	view →
LUSC	DFS	Median	All	0.923	0.652	.037	3	view →
BLCA	OS	Median	II,III,IV	1.000	0.411	.046	2	view →
SKCM	DFS	Median	II,III,IV	0.933	0.667	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ATP2C1–SCLC (DFS)

Open the SCLC breakdown →